Indrani Franchini joined Alnylam in January 2022 and has over 20 years of global legal experience in a variety of legal and compliance roles. She has held multiple leadership positions providing legal, government investigations, regulatory, governance, privacy, quality, compliance and commercial contracting counsel to a broad range of global functions.
Prior to joining Alnylam, Indrani served as Executive Vice President, Chief Compliance Officer at Alexion, and was a member of the executive team. Over her four years in this role, Indrani built and led a 300+ person global organization focused on risk management, including compliance, quality, and all aspects of policy, training, reporting, internal and external investigation, and communication.
Prior to Alexion, Indrani spent five years in legal and compliance roles functioning as Chief Compliance Officer and Assistant Corporate Secretary for Hess Corporation, a Fortune Global 500 leader in oil and gas exploration and production. Before Hess, Indrani spent almost ten years at Pfizer in various positions, including supporting the Global Pharmaceutical business. She began her career practicing corporate and transactional law at Milbank LLP, where she spent six years working in their New York and Tokyo offices.
Indrani received her Bachelor of Arts from Princeton University, her Juris Doctorate from the University of Michigan Law School, and served as a Fullbright Fellow at Kyushu University Graduate School in Fukuoka, Japan.
What is Indrani Lall Franchini's net worth?
The estimated net worth of Indrani Lall Franchini is at least $857,115.00 as of February 2nd, 2023. Ms. Franchini owns 3,500 shares of Alnylam Pharmaceuticals stock worth more than $857,115 as of November 23rd. This net worth estimate does not reflect any other investments that Ms. Franchini may own. Learn More about Indrani Lall Franchini's net worth.
How do I contact Indrani Lall Franchini?
Has Indrani Lall Franchini been buying or selling shares of Alnylam Pharmaceuticals?
Indrani Lall Franchini has not been actively trading shares of Alnylam Pharmaceuticals in the last ninety days. Most recently, Indrani Lall Franchini sold 3,500 shares of the business's stock in a transaction on Thursday, April 6th. The shares were sold at an average price of $210.00, for a transaction totalling $735,000.00. Learn More on Indrani Lall Franchini's trading history.
Who are Alnylam Pharmaceuticals' active insiders?
Alnylam Pharmaceuticals' insider roster includes Dennis Ausiello (Director), Michael Bonney (Director), Jeffrey Dunn (CEO), Kevin Fitzgerald (EVP), Indrani Franchini (EVP), Pushkal Garg (CMO), Yvonne Greenstreet (COO), Laurie Keating (EVP), John Maraganore (CEO), Steven Paul (Director), Jeffrey Poulton (CFO), David Pyott (Director), Amy Schulman (Director), Phillip Sharp (Director), Tolga Tanguler (EVP), and Akshay Vaishnaw (Insider). Learn More on Alnylam Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Alnylam Pharmaceuticals?
In the last year, insiders at the biopharmaceutical company sold shares 11 times. They sold a total of 154,848 shares worth more than $34,733,444.48. The most recent insider tranaction occured on August, 20th when CEO Yvonne Greenstreet sold 15,000 shares worth more than $4,200,000.00. Insiders at Alnylam Pharmaceuticals own 1.5% of the company.
Learn More about insider trades at Alnylam Pharmaceuticals. Information on this page was last updated on 8/20/2024.
